BLA 103172 · Genentech
Activase
Alteplase · Single-Use
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Nov 13, 1987
Approved uses
5
Original approval plus efficacy supplements
Registered trials
377
152 Phase 3, 54 recruiting
FAERS reports
15,039
10,406 serious, 3,242 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 20, 2026.
INDICATIONS AND USAGE Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 4, 2005 Supplement 5071 · Efficacy Label
- Sep 4, 2001 Supplement 5003 · Efficacy LabelLetter
- Jun 18, 1996 Supplement 1055 · Efficacy · priority review ReviewLetter
- Apr 3, 1995 Supplement 1036 · Efficacy · priority review
- Nov 13, 1987 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- ACTIVASE · ALTEPLASE 50MG/VIAL · VIAL, SINGLE-USE · Prescription
- CATHFLO ACTIVASE · ALTEPLASE 2MG/VIAL · VIAL, · Prescription
- ACTIVASE · ALTEPLASE 100MG/VIAL · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alteplase" as an intervention, any sponsor and status, largest first.
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632Pivotal-lookingRecruiting
University of CalgaryAcademic, hospital or other
NCT06320431 · 4,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 30, 2030
Drug: Tenecteplase · For: Acute Ischemic Stroke AIS; Stroke Acute; Stroke, Acute, Stroke Ischemic
Sites: Sydney, Australia; Melbourne, Australia; Calgary, Canada · 24 sites in all
- STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial InfarctionPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00623623 · 1,899 participants · Start Mar 1, 2008 · Primary completion Sep 1, 2012
Drug: enoxaparin; tenecteplase and 1 more · For: Myocardial Infarction
Sites: Salzburg, Austria; Vienna, Austria; Bornem, Belgium · 201 sites in all
- Alteplase-Tenecteplase Trial Evaluation for Stroke ThrombolysisPivotal-lookingCompleted
NHS Greater Glasgow and ClydeAcademic, hospital or other
NCT02814409 · 1,858 participants · Start Dec 15, 2016 · Primary completion Aug 31, 2023
Drug: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase; Intravenous Tenecteplase · For: Ischemic Stroke
Sites: Glasgow, United Kingdom
Boehringer IngelheimBoehringer Ingelheim
NCT00168792 · 1,671 participants · Start Nov 2003 · Primary completion Jul 2006
Drug: Tenecteplase · For: Myocardial Infarction
Sites: Little Rock, Arkansas; Fort Lauderdale, Florida; St. Petersburg, Florida · 176 sites in all
- Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)Pivotal-lookingStatus unknown
Beijing Tiantan HospitalAcademic, hospital or other
NCT05745259 · 1,630 participants (planned) · Start Oct 26, 2022 · Primary completion Nov 4, 2023
Drug: Alteplase; Tenecteplase · For: Acute Ischemic Stroke
Sites: Xuancheng, China; Beijing, China; Chongqing, China · 63 sites in all
- Alteplase Compared to Tenecteplase in Patients With Acute Ischemic StrokePivotal-lookingCompleted
University of CalgaryAcademic, hospital or other
NCT03889249 · 1,600 participants · Start Dec 10, 2019 · Primary completion Apr 26, 2022
Drug: Tenecteplase; Alteplase · For: Stroke, Acute; Thromboses, Intracranial
Sites: Calgary, Canada; Edmonton, Canada; Medicine Hat, Canada · 22 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event2,541
- off label use1,883
- death1,194
- gingival bleeding1,031
- cerebral haemorrhage827
- haemorrhage intracranial741
- drug ineffective646
- angioedema631
- haemorrhage577
- haemorrhagic transformation stroke441
- product storage error391
- nausea372
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 68 |
| 2005 | 64 |
| 2006 | 64 |
| 2007 | 95 |
| 2008 | 137 |
| 2009 | 241 |
| 2010 | 138 |
| 2011 | 201 |
| 2012 | 1,027 |
| 2013 | 926 |
| 2014 | 422 |
| 2015 | 399 |
| 2016 | 897 |
| 2017 | 1,847 |
| 2018 | 850 |
| 2019 | 395 |
| 2020 | 711 |
| 2021 | 868 |
| 2022 | 1,039 |
| 2023 | 799 |
| 2024 | 2,836 |
| 2025 | 604 |
| 2026 | 411 |
Recalls
2 FDA enforcement reports for this application.
May 20, 2024 · Class II · Terminated
Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated May 21, 2026
Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27). Discontinuation of the 100mg vial configuration
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Activase* (Alteplase*) · HCPCS J2997
2024 spending
$19.2M
Beneficiaries
37,622
58,839 claims
Per beneficiary
$509
2024 ASP limit $90.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $56,279,564 |
| 2021 | $51,146,680 |
| 2022 | $39,948,592 |
| 2023 | $27,390,505 |
| 2024 | $19,161,773 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials.
Palaiodimou L, Katsanos AH, Turc G, et al. · Neurology 2024 · Systematic Review, Meta-Analysis
- Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.
Meng X, Li S, Dai H, et al. · JAMA 2024 · Clinical Trial, Phase III, Comparative Study
- Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial.
Zhou Y, He Y, Campbell BCV, et al. · JAMA 2025 · Clinical Trial, Phase III, Multicenter Study
- Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Menon BK, Buck BH, Singh N, et al. · Lancet 2022 · Multicenter Study, Randomized Controlled Trial
- Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours.
Yan S, Zhou Y, Lansberg MG, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Emberson J, Lees KR, Lyden P, et al. · Lancet 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Roche (Genentech) · Also marketed as Cathflo Activase
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.